Skyline Vet Pharma is an emerging animal health product development and marketing company that reformulates human drugs for companion animals using proven, in-licensed delivery technologies. The company is building franchises in three therapeutic areas—pain/inflammation, cardiovascular disease and antimicrobials—that together represent more than 60% of veterinarians' prescriptions. Skyline intends to bring several new products to market over the next few years, prioritizing palatable formulations, easier administration and less frequent dosing to improve treatment compliance. The company was co-founded by Serge Martinod, D.V.M., Ph.D. (CEO) and George Murphy (VP), who together bring nearly 60 years of industry experience. Founded in 2015, Skyline recently completed a $5 million Series A financing from AgTech Accelerator and its syndicate partners. Its business model focuses on repositioning human drugs not yet approved for animal health into novel combination products for established companion-animal markets.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2017